---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-080568"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2025-06-03T23:59:59+00:00"
generated_at: "2026-05-20T02:09:54.895265+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# Perspective Therapeutics unveils updated corporate presentation with clinical progress

## Summary
- Updated presentation highlights [212Pb]VMT-α-NET Phase 1/2a for neuroendocrine tumors with sustained anti-tumor activity and tolerability.
- Melanoma program [212Pb]VMT01 Phase 1/2a trial for metastatic melanoma includes TEAE safety data and trial design.
- PSV359 Phase 1/2a trial targets FAP-α expression on tumor and stroma for multiple cancers.
- Company describes pre-targeting platform and on-demand supply chain for regional radiopharmaceutical delivery.

## SEC filing metadata
- accession: 0000950170-25-080568
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2025-06-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000095017025080568/0000950170-25-080568-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000095017025080568/catx-20250603.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-080568
- JSON: https://secwatch.observer/filing/0000950170-25-080568.json
- Plain text: https://secwatch.observer/filing/0000950170-25-080568.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.